The CMS Innovation Center paid $2.6 billion through September to hospitals, doctors and others through nearly two dozen programs that tested new ways to deliver healthcare and pay for it.
SHUTTLE Pharmaceuticals, a privately held company, today announced it has been awarded a fast-track Phase I/II contract #HHSN261201400013C by the National Institutes of Health (NIH) under its Small Business Innovation Research (SBIR) program. The $ 1.62 million contract will fund the initial development of IPdR (5-iodo-2-pyrimidinone-2-deoxyribose), a prodrug of the radiation sensitizer IUdR (5-iodo-2-deoxyuridine). The contract is to determine the scientific merit, feasibility and potential for commercialization of oral IPdR for use as a radiation sensitizer for the treatment of rectal cancers. The NIH contract provides funds to cover a portion of the costs for initiating a Phase I trial in GI cancers and development of companion diagnostics for analyzing clinical specimens from Phase I patients.
Ah, the elevator pitch. A favorite tool of the networking masses. A rite of passage of sorts. You’ve heard the scenario: you step into an elevator and go up one floor. The elevator doors open and in walks the client of your dreams. They start some small talk and ask, “What do you do?” and you’ve got the rest of the elevator ride to respond. How do you answer that in 20 seconds in such a way that gets them interested? The answer is simple. You need an elevator pitch for your elevator pitch.
Roche Holding AG said US health regulators have approved its Ebola test for emergency use in response to the world’s worst outbreak of the disease in West Africa.
The US Food and Drug Administration (FDA) has approved Roche’s LightMix Ebola Zaire rRT-PCR Test for use on patients with signs and symptoms of Ebola Zaire virus infection, the Swiss drugmaker said in a statement.
In 2014, wearable health tracking devices continued to get more creative, going far beyond simple fitness tracking. The K-Goal, a “Fitbit for your vagina,” promised to help women do kegel exercises correctly, while the Emotiv EEG headset offered the prospect of mental acuity, measured by a device that tracks the brain’s concentration.
The year in biotechnology began with a landmark event. A decade after the first human genome was decoded at a cost of about $3 billion, the sequencing-machine company Illumina, of San Diego, introduced a new model, the Hyseq X-10, that can do it for around $1,000 per genome.
A new business incubator in Baltimore’s Inner Harbor will cater to startup companies launched through universities.
The Institute of Marine & Environmental Technology in January is opening a 4,300-square-foot incubator in its offices at the Christopher Columbus Center in Baltimore’s Inner Harbor.
Medical technology developer Medtronic, Inc. recently completed an application submission to the U.S. Food and Drug Administration (FDA) regarding the pre-market approval of their SynchroMed II implantable drug infusion system, which includes a new catheter design. The system is intended to be used by pulmonary arterial hypertension (PAH) patients for the intravenous delivery of the drug Remodulin (treprostinil), which is being developed by the United Therapeutics Corporation.
Here are my 10 crucial pieces of advice for students who aspire to a career in pharmaceutical labs:
1. You need a solid foundation in science. Master the basics, and learn how to apply that knowledge.
Biotechnology will have a strong year in 2015, but it can’t get any better than 2014, biotech investor G. Steven Burrill says in his annual year-end report.
“The unprecedented IPO (initial public offering) and M&A (mergers and acquisitions) activity this year will make 2014 one for the record books and unlikely to ever be surpassed,” Burrill said.